Cite
HARVARD Citation
Danta, M. (2012). Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection. Evidence-based medicine. 17 (5), pp. 143-144. [Online].